Graham Clarke at the Breath Biopsy Conference 2021

The Breath Biopsy Conference 2022 is scheduled for 1^st-3^rd November. Click the button to express interest in the next Breath Biopsy Conference:

Express Interest

Talk Abstract:

The number of breath biomarker discovery trials has increased in recent years with the discovery of potential breath volatile biomarkers across multiple studies. The adoption of breath into large scale studies such as U-BIOPRED, EMBER and most recently 3TRIMI confirms the interest of the respiratory research community, including pharma, in this technology. However we are now at a critical stage. To date the mounting evidence supports breath VOC biomarkers at the proof-of-concept level, but no tests have yet penetrated through to clinical practice. A number of key elements need to be addressed to develop confidence in this technology, notably amongst others; reproducibility, pre-analytical competencies, VOC stability, the robustness of data and its synergy with more established ‘omic’ approaches. The path for adoption in drug discovery and development modalities are manifold, but the presentation will continue to address its utility as a tool for target-candidate identification and progressively to inform diagnosis, early detection and phenotyping of disease. This puts breath analysis at an exciting time where it is at the cusp of having true impact in clinic. The presentation further explores requirements for the next decade of breath research.

Speaker Biography:

Graham Clarke is the Head of Translational Science and Experimental Medicine Operations for Early Respiratory & Immunology at AstraZeneca. His role is to develop and evolve the operating infrastructures to enable the precision medicine strategy across the Early R&I portfolio. Graham has a PhD from King’s College London, UK, in Respiratory Pharmacology and Physiology. He comes with 20 years of clinical operation and clinical model development experience, with specific focus on inhaled challenge models of inflammation and non-invasive methods of measuring airway inflammation. Prior to joining AZ, Graham held increasing levels of responsibility at Quintiles Drug Research Unit, latterly leading the Respiratory early clinical development group first in man and first in patient drug trials, and more recently at Hvivo Ltd. as Head of Clinical Operations and virus challenge model development. Graham is the AZ lead for the 3TR-IMI consortium, a Pan-European cross-disease research consortium aimed at improving personalized biological treatment of asthma and COPD. He also leads the 3TR Breathomics working group to critically evaluate its utility and incorporation in 3TR sponsored clinical trials and its broader adoption in drug discovery research.

The Breath Biopsy Conference 2022 is scheduled for 1^st-3^rd November. Click the button to express interest in the next Breath Biopsy Conference:

Express Interest